Clinicogenomic Radiotherapy Classifier Predicting the Need for Intensified Locoregional Treatment After Breast-Conserving Surgery for Early-Stage Breast Cancer
Overview
Authors
Affiliations
Purpose: Most patients with early-stage breast cancer are treated with adjuvant radiotherapy (RT) after breast-conserving surgery (BCS) to prevent locoregional recurrence (LRR). However, no genomic tools are used currently to select the optimal RT strategy.
Methods: We profiled the transcriptome of primary tumors on a clinical grade assay from the SweBCG91-RT trial, in which patients with node-negative breast cancer were randomly assigned to either whole-breast RT after BCS or no RT. We derived a new classifier, Adjuvant Radiotherapy Intensification Classifier (ARTIC), comprising 27 genes and patient age, in three publicly available cohorts, then independently validated ARTIC for LRR in 748 patients in SweBCG91-RT. We also compared previously published genomic signatures for ability to predict benefit from RT in SweBCG91-RT.
Results: ARTIC was highly prognostic for LRR in patients treated with RT (hazard ratio [HR], 3.4; 95% CI, 2.0 to 5.9; < .001) and predictive of RT benefit ( = .005). Patients with low ARTIC scores had a large benefit from RT (HR, 0.33 [95% CI, 0.21 to 0.52], < .001; 10-year cumulative incidence of LRR, 6% 21%), whereas those with high ARTIC scores benefited less from RT (HR, 0.73 [95% CI, 0.44 to 1.2], = .23; 10-year cumulative incidence of LRR, 25% 32%). In contrast, none of the eight previously published signatures were predictive of benefit from RT in SweBCG91-RT.
Conclusion: ARTIC identified women with a substantial benefit from RT as well as women with a particularly elevated LRR risk in whom whole-breast RT was not sufficiently effective and, thus, in whom intensified treatment strategies such as tumor-bed boost, and possibly regional nodal RT, should be considered. To our knowledge, ARTIC is the first classifier validated as predictive of benefit from RT in a phase III clinical trial with patients randomly assigned to receive or not receive RT.
Egelberg M, De Marchi T, Schultz N, Tran L, Karlsson P, Holmberg E BMC Cancer. 2025; 25(1):374.
PMID: 40022029 PMC: 11869729. DOI: 10.1186/s12885-025-13703-1.
Dai D, Li X, Zhuang H, Ling Y, Chen L, Long C Adv Sci (Weinh). 2024; 12(1):e2308174.
PMID: 39494578 PMC: 11714210. DOI: 10.1002/advs.202308174.
Karlsson P, Fyles A, Chang S, Arrick B, Baehner F, Malmstrom P J Natl Cancer Inst. 2024; 117(3):486-495.
PMID: 39423142 PMC: 11884857. DOI: 10.1093/jnci/djae262.
Gruber G Cancers (Basel). 2024; 16(17).
PMID: 39272804 PMC: 11394564. DOI: 10.3390/cancers16172946.
Zhang Z, Xia Y, Li X, Zhang Q, Wu Y, Cui C Bioact Mater. 2024; 40:667-682.
PMID: 39257958 PMC: 11386050. DOI: 10.1016/j.bioactmat.2024.08.014.